Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients.
Newling M, Fiechter RH, Sritharan L, Hoepel W, van Burgsteden JA, Hak AE, van Vollenhoven RF, van de Sande MGH, Baeten DLP, den Dunnen J. Newling M, et al. Among authors: van vollenhoven rf, van de sande mgh, van burgsteden ja. Clin Exp Immunol. 2020 Jan;199(1):39-49. doi: 10.1111/cei.13371. Epub 2019 Oct 7. Clin Exp Immunol. 2020. PMID: 31509231 Free PMC article. Clinical Trial.
IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study.
Al-Soudi A, Doorenspleet ME, Esveldt RE, Burgemeister LT, Hak AE, van den Born BJH, Tas SW, van Vollenhoven RF, Klarenbeek PL, de Vries N. Al-Soudi A, et al. Among authors: van vollenhoven rf, van den born bjh. Arthritis Res Ther. 2019 Jan 31;21(1):43. doi: 10.1186/s13075-018-1806-6. Arthritis Res Ther. 2019. PMID: 30704507 Free PMC article.
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
Cesaroni M, Seridi L, Loza MJ, Schreiter J, Sweet K, Franks C, Ma K, Orillion A, Campbell K, M Gordon R, Branigan P, Lipsky P, van Vollenhoven R, Hahn BH, Tsokos GC, Chevrier M, Rose S, Baribaud F, Jordan J. Cesaroni M, et al. Arthritis Rheumatol. 2021 Mar;73(3):472-477. doi: 10.1002/art.41547. Epub 2021 Feb 1. Arthritis Rheumatol. 2021. PMID: 33010188 Free PMC article. Clinical Trial.
Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Hellamand P, van de Sande MGH, Nurmohamed MT, van Vollenhoven RF, Hollick RJ, Rotariu O, Rotar Z, Pirkmajer KP, Nordström D, Hokkanen AM, Michelsen B, Kvien TK, Glintborg B, Hetland ML, Østergaard M, Loft AG, Pavelka K, Zavada J, Castrejon I, Otero-Varela L, Gudbjornsson B, Palsson O, Olofsson T, Wallman JK, Ciurea A, Nissen MJ, Yildirim TD, Onen F, Codreanu C, Mogosan C, Santos MJ, Vieira-Sousa E, Iannone F, Frediani B, Ørnbjerg LM, Twisk JWR, van der Horst-Bruinsma IE. Hellamand P, et al. Among authors: van vollenhoven rf. Rheumatology (Oxford). 2024 Jul 23:keae370. doi: 10.1093/rheumatology/keae370. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39041780
Anti-C1q antibodies in systemic lupus erythematosus.
Orbai AM, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcón GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow CB, Manzi S, Urowitz MB, Gladman DD, Kalunian KC, Costner MI, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS, Petri M. Orbai AM, et al. Among authors: van vollenhoven rf. Lupus. 2015 Jan;24(1):42-9. doi: 10.1177/0961203314547791. Epub 2014 Aug 14. Lupus. 2015. PMID: 25124676 Free PMC article.
The frequency and outcome of lupus nephritis: results from an international inception cohort study.
Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. Hanly JG, et al. Among authors: van vollenhoven rf. Rheumatology (Oxford). 2016 Feb;55(2):252-62. doi: 10.1093/rheumatology/kev311. Epub 2015 Sep 5. Rheumatology (Oxford). 2016. PMID: 26342222 Free PMC article.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.
Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B. Rovin BH, et al. Among authors: van vollenhoven rf. Arthritis Rheumatol. 2016 Sep;68(9):2174-83. doi: 10.1002/art.39722. Arthritis Rheumatol. 2016. PMID: 27110697 Free PMC article. Clinical Trial.
485 results